multi kinases inhibitors
Showing 1 - 25 of >10,000
Digestive Cancer, Metastatic Colorectal Cancer, Hepatocellular Carcinoma Trial in France (Blood sampling to build population
Recruiting
- Digestive Cancer
- +4 more
- Blood sampling to build population pharmacokinetics model
-
Auxerre, France
- +23 more
Aug 30, 2022
Inhibitors of Jak Kinases in Patients With Rheumatoid Arthritis.
Recruiting
- Arthritis, Rheumatoid
-
Sevilla, SpainHospital Universitario Virgen macarena
Nov 15, 2021
Breast Cancer Trial (Chidamide+ Fulvestrant)
Not yet recruiting
- Breast Cancer
- Chidamide+ Fulvestrant
- (no location specified)
Jan 13, 2022
Liver Transplant; Complications, Hepatocarcinoma, Recurrent Osteosarcoma Trial in Beijing (multi-kinase inhibitors in
Not yet recruiting
- Liver Transplant; Complications
- +3 more
- multi-kinase inhibitors in combination with bevacizumab
-
Beijing, Beijing, ChinaChinese Academy of Medical Sciences & Peking Union Medical Colle
Sep 11, 2023
Plasmid Inhibitors and Antimicrobial Drugs Against Clinical
Not yet recruiting
- Synergy Between Plasmid Inhibitors and Combined Antibiotics
- (no location specified)
Jun 27, 2023
Diabetes, Type 1 Trial (Abrocitinib 200 MG Oral Tablet, Ritlecitinib, Placebo)
Not yet recruiting
- Diabetes Mellitus, Type 1
- Abrocitinib 200 MG Oral Tablet
- +2 more
- (no location specified)
Feb 21, 2023
Proton Pump Inhibitors, Deprescription Trial in Nantes (General practitioner and Patient receive informations related to PPI
Completed
- Proton Pump Inhibitors
- Deprescription
- General practitioner and Patient receive informations related to PPI deprescribing.
- Only General practitioner receive informations related to PPI deprescribing.
-
Nantes, FranceUniversity Hospital
Sep 22, 2022
Neuroendocrine Tumors, NET, Pancreatic Neuroendocrine Tumor Trial in Newport Beach, Denver, Dallas (nab-sirolimus)
Not yet recruiting
- Neuroendocrine Tumors
- +4 more
-
Newport Beach, California
- +2 more
Aug 16, 2023
Left Ventricular Remodeling in Type 2 Diabetic Acute Myocardial
Recruiting
- Myocardial Infarction
- Diabetes Mellitus, Type 2
- SGLT2 inhibitor
-
Seoul, Korea, Republic ofSeoul St. Mary's Hospital
Mar 5, 2023
Colorectal Cancer, Microsatellite Instability High Trial in Guangzhou (PD-1 inhibitor plus VEGF inhibitors)
Recruiting
- Colorectal Cancer
- Microsatellite Instability High
- PD-1 inhibitor plus VEGF inhibitors
-
Guangzhou, Guangdong, China651 Dongfeng Road East
May 27, 2022
Empa PASS on Urinary Tract Malignancies
Active, not recruiting
- Diabetes Mellitus, Type 2
- empagliflozin
- +2 more
-
Helsinki, Finland
- +2 more
Aug 8, 2022
Proton Pump Inhibitors, Deprescription Trial in Nantes (GP will receive the educational outreach visit by a DAM (healthcare
Not yet recruiting
- Proton Pump Inhibitors
- Deprescription
- GP will receive the educational outreach visit by a DAM (healthcare representative).
- Patient education material on PPI deprescribing will be sent to the patients
-
Nantes, FranceUniversity Hospital
Dec 3, 2021
Advanced or Metastatic Urothelium Cancer Trial in Beijing (MRG002, Docetaxel Injection, Paclitaxel Injection)
Not yet recruiting
- Advanced or Metastatic Urothelium Cancer
- MRG002
- +4 more
-
Beijing, Beijing, ChinaCancer Hospital Chinese Academy of Medical Sciences
Feb 22, 2023
Single-ventricle, Pulmonary Hypertension, Univentricular Heart Trial (Sildenafil, Placebos)
Not yet recruiting
- Single-ventricle
- +2 more
- Sildenafil
- Placebos
- (no location specified)
Jan 20, 2022
Stage III Melanoma, Stage IV Melanoma Trial in Los Angeles, Denver (TBX-3400)
Recruiting
- Stage III Melanoma
- Stage IV Melanoma
- TBX-3400
-
Los Angeles, California
- +1 more
May 1, 2022
Vascular Access Complication Trial in Rawalpindi (Losartan Potassium, multi-vitamins)
Recruiting
- Vascular Access Complication
- Losartan Potassium
- multi-vitamins
-
Rawalpindi, Punjab, PakistanAnas Bin Saif
Nov 22, 2021
Chronic Hepatitis B Trial in Hong Kong, Auckland (VRON-0200-AdC6, VRON-0200-AdC7)
Recruiting
- Chronic Hepatitis B
- VRON-0200-AdC6
- VRON-0200-AdC7
-
Hong Kong, Hong Kong
- +1 more
Oct 6, 2023
Esophageal Squamous Cell Carcinoma Trial in Hefei (Hybrid dose-fraction Radiotherapy combined with immune checkpoint inhibitors)
Recruiting
- Esophageal Squamous Cell Carcinoma
- Hybrid dose-fraction Radiotherapy combined with immune checkpoint inhibitors
-
Hefei, Anhui, ChinaAnhui Provicial Hospital
Apr 26, 2022
HIV-1-infection, Multi-Antiviral Resistance Trial in Milan (REGISTER CREATION)
Recruiting
- HIV-1-infection
- Multi-Antiviral Resistance
- REGISTER CREATION
-
Milan, MI, ItalyOspedale San Raffaele
Dec 22, 2021
Radiomics, Hepatocellular Carcinoma (HCC), Transcatheter Arterial Chemoembolization (TACE) Trial in Guangzhou (Sorafenib,
Active, not recruiting
- Radiomics
- +4 more
-
Guangzhou, Guangdong, ChinaThe First Affiliated Hospital of Sun Yat-sen University
Jun 5, 2023
Recurrent Cervical Carcinoma, Persistent Advanced Cervical Carcinoma, Chemo Trial in Beijing (Anti-PD-1 antibody camrelizumab,
Recruiting
- Recurrent Cervical Carcinoma
- +5 more
- Anti-PD-1 antibody camrelizumab
- Albumin-bound paclitaxel
-
Beijing, Beijing, ChinaLei Li
Mar 12, 2022
Radiotherapy, PD-1 Inhibitor, Capecitabine Trial in Zhuhai (SBRT radiotherapy + Conventionally fractionated radiotherapy, PD-1
Recruiting
- Radiotherapy
- +3 more
- SBRT radiotherapy + Conventionally fractionated radiotherapy
- +2 more
-
Zhuhai, Guangdong, ChinaFifth Affilliated Hospital of Sun Yat-sen University
Apr 13, 2022
Leukemia, Chronic Myelogenous Trial in China (asciminib, best available treatment)
Recruiting
- Leukemia, Chronic Myelogenous
- asciminib
- best available treatment
-
Chongqing City, Chongqing, China
- +23 more
Jan 18, 2023